Gerresheimer has announced plans to separate its Moulded Glass business unit and begin a formal sales process. This decision follows a strategic review aimed at identifying the best opportunities for long-term growth and competitiveness. The company concluded that the Moulded Glass business has greater growth potential outside the Gerresheimer Group.
“As part of our strategic transformation, Gerresheimer will focus even stronger on systems and solutions for the pharma and biotech industry,” said CEO Dietmar Siemssen. “We see the best growth opportunities for our newly formed Moulded Glass Powerhouse outside the Gerresheimer Group.”
The Moulded Glass unit, now combined with Bormioli Pharma’s glass business, includes eight production facilities in Germany, Belgium, Italy, the United States, and India. It employs around 3,700 people and generated pro forma revenues of approximately €735 million in the 2024 financial year, with an adjusted EBITDA margin of 20%. The unit specialises in Type I, II, and III moulded glass for the pharmaceutical, cosmetics, and food and beverage industries. Its portfolio includes bottles, jars, flacons, and custom glass packaging with decoration capabilities.
Gerresheimer has consistently invested in the modernisation of its glass operations, including a €100 million upgrade at its Lohr am Main facility in Germany, featuring a new energy-efficient oxy-hybrid furnace. 
The separation process marks the first step in establishing the Moulded Glass unit as a global standalone business. Gerresheimer plans to provide further updates during its Capital Markets Day on October 15, 2025.
Source: Gerresheimer with additional information added by Glass Balkan
